Authors disclosed final efficacy and safety data from the Phase I/II ARROW study of pralsetinib in patients with advanced RET fusion-positive non–small cell lung cancer. The manuscript provides disclosure details tied to relationships and funding, reflecting ongoing consolidation of evidence as pralsetinib continues to be evaluated across lines of therapy in RET-driven disease.